AstraZeneca is a global pharmaceutical company that focuses on creating medicines in areas like oncology and rare diseases. The company faces ongoing pressure from generic drug competition, which makes its earnings reports a key indicator of its performance. Its shares previously traded on Nasdaq but now trade on the New York Stock Exchange.
On July 27, 2026, AstraZeneca announced its quarterly financial results. The company reports a core earnings per share (EPS) of $2.63. This figure surpasses the consensus analyst estimate of $2.50. This result represents a significant 21% increase in earnings compared to the same quarter in the previous year.
For the quarter, total revenue reached $15.38 billion. This amount fell just short of the anticipated $15.40 billion forecast but still marks a 6% rise from the prior year. Strong sales from key drugs in its oncology and rare disease segments drove this growth, helping to balance the impact of rising generic competition.
Following the earnings announcement, shares in AstraZeneca climbed to their highest point in over two weeks, as highlighted by Proactive Investors. The company also reaffirmed its guidance for 2026, projecting mid-to-high single-digit revenue growth. Chief Executive Pascal Soriot expressed confidence in meeting the company's long-term ambitions, as reported by GuruFocus.
From a valuation standpoint, AstraZeneca has a Price-to-Earnings (P/E) ratio of 12.65, which helps investors gauge its market value relative to its earnings. The company's financial health shows a Debt-to-Equity ratio of 0.72. This metric indicates that the company uses a mix of debt and its own funds to finance its assets.
